Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 3, 2015-03 ,pp. : 268-275

John Wiley & Sons Inc

Access to resources Recommend Favorite

Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial

By Umpierrez Guillermo   Issa Maher   Vlajnic Aleksandra  

Current Medical Research and Opinion, Vol. 22, Iss. 4, 2006-04 ,pp. : 751-759

Informa Healthcare

Access to resources Recommend Favorite

Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study

By Hanefeld M.   Pfützner A.   Forst T.   Lübben G.  

Current Medical Research and Opinion, Vol. 22, Iss. 6, 2006-06 ,pp. : 1211-1215

Informa Healthcare

Access to resources Recommend Favorite

Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 4, 2015-04 ,pp. : 409-414

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study

By Williams-Herman Debora   Johnson Jeremy   Teng Rujun   Luo Edmund   Davies Michael J.   Kaufman Keith D.   Goldstein Barry J.   Amatruda John M.  

Current Medical Research and Opinion, Vol. 25, Iss. 3, 2009-03 ,pp. : 569-583

Informa Healthcare

Access to resources Recommend Favorite